T207. METABOLIC ADVERSE EFFECTS OF OFF-LABEL USE OF SECOND-GENERATION ANTIPSYCHOTICS IN THE ADULT POPULATION: A SYSTEMATIC REVIEW AND META-ANALYSIS

BACKGROUND: Second generation antipsychotics (SGAs) are approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia, bipolar disorder and treatment refractory depression. Since the late 1990’s, prescription of antipsychotics has more than doubled and off-label use (i.e....

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Schizophr Bull
Autors principals: Bowden, Sylvie, Tran, Veronica, Asgariroozbehani, Roshanak, Brett McIntyre, William, Agarwal, Mahavir, Siskind, Dan, Hahn, Margaret
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2020
Matèries:
Poster Session III
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7234501/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/schbul/sbaa029.767
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars